If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.745    0.27 (7.77%)
Bid:
3.50
Ask:
3.995
Spread: 0.495 (14.143%)
Market Cap: £23.37m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Directorate Change

30 Sep 2015 07:05

RNS Number : 6273A
Immupharma PLC
30 September 2015
Β 

Β 

FOR IMMEDIATE RELEASE

30 SEPTEMBER 2015

Β 

Β 

Β 

TIM MCCARTHY APPOINTED AS NON-EXECUTIVE CHAIRMAN

Β 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.

Β 

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Β 

A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

Β 

Β 

Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said:

Β 

"We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy."

Β 

Β 

Current Directorships

Ark Analytics Solutions Limited

BBN International Limited

Dropped Limited

Expedeon Holdings Limited

Frangipani Dreams Limited

Harvard Healthcare Limited

Incanthera Limited

Spear Therapeutics Limited

Unnamed Limited

Wise Old Owl Limited

Β 

Directorships in the Last 5 years

Retail Service Team Limited*

Β 

\* This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015.

Β 

Β 

Β 

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Β 

For further information please contact:

Β 

ImmuPharma plc

+ 44 (0) 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413 496

Panmure, Gordon & Co., NOMAD & Broker

+ 44 (0) 20 7886 2500

Fred Walsh, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAPKCDNOBKDNCB
Date   Source Headline
2nd Jun 20207:00 amRNSNotification of Change of AGM Venue
21st May 20207:00 amRNSNotice of AGM and posting of Report & Accounts
18th May 20201:45 pmRNSTR-1: Notification of major holdings
14th May 20207:00 amRNSEfforts in fight vs Covid-19 with Lupuzor; Ureka
30th Apr 20209:57 amRNSAudited Report & Accounts published on website
30th Apr 20207:00 amRNSFINAL RESULTS FOR THE 12M ENDED 31/12/19
6th Apr 20207:00 amRNSIMM live on Investor Meet Company platform 7 April
3rd Apr 20203:55 pmRNSHolding(s) in Company
2nd Apr 20208:26 amRNSHolding(s) in Company
31st Mar 202012:07 pmRNSSecond Price Monitoring Extn
31st Mar 202012:02 pmRNSPrice Monitoring Extension
30th Mar 20208:02 amRNS£1.5m Subscrip'n to fund R&D pipeline- replacement
30th Mar 20207:00 amRNS£1.5m Subscription to fund R&D pipeline expansion
20th Mar 20204:45 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:39 pmRNSPrice Monitoring Extension
4th Mar 20204:35 pmRNSPrice Monitoring Extension
28th Feb 20207:03 amRNSIncanthera plc – Admission to trading on NEX
21st Feb 20204:35 pmRNSPrice Monitoring Extension
17th Feb 20208:00 amRNSIncanthera announces Rule 23 Notice re NEX listing
12th Feb 20204:41 pmRNSSecond Price Monitoring Extn
12th Feb 20204:35 pmRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSUpdate on the Avion Agreement
5th Feb 20204:40 pmRNSSecond Price Monitoring Extn
5th Feb 20204:35 pmRNSPrice Monitoring Extension
7th Jan 20204:40 pmRNSSecond Price Monitoring Extn
7th Jan 20204:35 pmRNSPrice Monitoring Extension
19th Dec 20194:35 pmRNSPrice Monitoring Extension
19th Dec 20197:00 amRNSAdmission today to trading on Euronext Growth
17th Dec 20197:00 amRNSPublication of Information Note (Euronext Growth)
13th Dec 20197:00 amRNSDual Listing on Euronext Growth Brussels
11th Dec 201912:49 pmRNSShare Price Volatility
3rd Dec 20197:00 amRNSIMMUPHARMA TO PRESENT AT BIOTECH SHOWCASET 2020
2nd Dec 20197:00 amRNSTR-1: notification of major holdings
28th Nov 20197:00 amRNSLicence Agreement for Lupuzor with Avion in US
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:35 pmRNSPrice Monitoring Extension
5th Nov 20194:41 pmRNSSecond Price Monitoring Extn
5th Nov 20194:35 pmRNSPrice Monitoring Extension
7th Oct 201912:07 pmRNSSecond Price Monitoring Extn
7th Oct 201912:02 pmRNSPrice Monitoring Extension
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
1st Oct 20194:40 pmRNSSecond Price Monitoring Extn
1st Oct 20194:35 pmRNSPrice Monitoring Extension
30th Sep 20197:00 amRNSInterim Results Announcement
18th Sep 20194:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.